Finance
2024.01.22
Lumosa Launching LT3001 Phase 2 Trials in Multiple EU Countries
Finance
2023.12.05
Lumosa’s Lead Candidate LT3001 for Acute Ischemic Stroke Approaching Key Milestone, Targeting Unblinding in Late 2024
Finance
2023.11.09
LT1001 Long-Acting Analgesic Injection Licensed in India
Corporate
2023.09.26
Lumosa's LT1001 Receives Approval from Brunei
Expanding its presence in Southeast Asian market
Corporate
2023.07.26
LT3001 Received Formulation Patent from USPTO
Corporate
2023.05.15
Lumosa’s LT1001 Received First European Approval from Ukraine’s SMDC